BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9436189)

  • 1. Use of hematopoietic hormones for bone marrow defects in AIDS.
    Aboulafia DM
    Oncology (Williston Park); 1997 Dec; 11(12):1827-34, 1839, 1843-4; discussion 1. PubMed ID: 9436189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies.
    Miles SA
    Cancer Invest; 1991; 9(2):229-38. PubMed ID: 1713806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical role of granulocyte-macrophage colony-stimulating factor.
    Mitsuyasu RT; Golde DW
    Hematol Oncol Clin North Am; 1989 Sep; 3(3):411-25. PubMed ID: 2698875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical use of hematopoietic growth factors.
    Appelbaum FR
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):7-14. PubMed ID: 2477905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematopoietic growth factors as supportive therapy in HIV-infected patients.
    Hermans P
    AIDS; 1995 Dec; 9 Suppl 2():S9-S14. PubMed ID: 8775801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of myeloid hematopoietic growth factors in patients with HIV infection.
    Mitsuyasu RT; Miles SA; Golde DW
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():347-54; discussion 354-5. PubMed ID: 1691250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte colony-stimulating factor: preclinical and clinical studies.
    Gabrilove JL; Jakubowski A
    Hematol Oncol Clin North Am; 1989 Sep; 3(3):427-40. PubMed ID: 2483722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer.
    Fan D; O'Brian CA; Ioannides CG; Clyne RK
    In Vivo; 1991; 5(6):571-7. PubMed ID: 1810441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematologic toxicity of zidovudine in HIV-infected patients.
    Brogan KL; Zell SC
    Am Fam Physician; 1990 May; 41(5):1521-8. PubMed ID: 1692180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic growth factors as adjuncts to antiretroviral therapy.
    Miles SA
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1073-80. PubMed ID: 1380256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of hematopoietic hormones in HIV infection and AIDS-related malignancies.
    Miles SA; Golde DW; Mitsuyasu RT
    Hematol Oncol Clin North Am; 1991 Apr; 5(2):267-80. PubMed ID: 2022593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical applications of recombinant human colony-stimulating factors.
    Klingemann HG
    CMAJ; 1989 Jan; 140(2):137-42. PubMed ID: 2642725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Report on the current indications for colony stimulating factors (G-CSF and GM-CSF)].
    Med Clin (Barc); 1994 May; 102(19):747-50. PubMed ID: 7518884
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current developments in the treatment of AIDS].
    Mulder JW
    Ned Tijdschr Geneeskd; 1989 Aug; 133(33):1664-6. PubMed ID: 2477718
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of GM-CSF in AIDS.
    Scadden DT
    Infection; 1992; 20 Suppl 2():S103-6. PubMed ID: 1283604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24.
    Rameshwar P; Denny TN; Gascón P
    J Immunol; 1996 Nov; 157(9):4244-50. PubMed ID: 8892663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.
    Miles SA; Mitsuyasu RT; Moreno J; Baldwin G; Alton NK; Souza L; Glaspy JA
    Blood; 1991 May; 77(10):2109-17. PubMed ID: 1709368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GM-CSF and G-CSF: cytokines in clinical application].
    Ruef C; Coleman DL
    Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.